The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...
Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
Scientists studying an aggressive cancer that affects thousands of dogs annually have uncovered a genetic signature that ...
The therapy is a critical treatment option for various life-threatening disease. Earlier, GST on gene therapy was set at 12 ...
A University of Florida research team has identified a crucial link between a gene mutation and immune system signaling in canine hemangiosarcoma, an aggressive cancer common in dogs. The discovery ...
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...
Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.